Relmada Therapeutics, Inc. (RLMD)
Largest Insider Buys in Sector
RLMD Stock Price History Chart
RLMD Stock Performance
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Insider Activity of Relmada Therapeutics, Inc.
Over the last 12 months, insiders at Relmada Therapeutics, Inc. have bought $1.31M and sold $0 worth of Relmada Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Relmada Therapeutics, Inc. have bought $726,912 and sold $1.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: TRAVERSA SERGIO (Chief Executive Officer) — $1.56M. Shenouda Maged (Chief Financial Officer) — $275,418. Ence Chuck (CA and CO) — $150,920.
The last purchase of 51,407 shares for transaction amount of $153,707 was made by TRAVERSA SERGIO (Chief Executive Officer) on 2024‑09‑11.
List of Insider Buy and Sell Transactions, Relmada Therapeutics, Inc.
| 2024-09-11 | Chief Executive Officer | 51,407 0.1813% | $2.99 | $153,707 | +9.36% | |||
| 2024-09-11 | Chief Financial Officer | 24,120 0.0839% | $2.95 | $71,154 | +10.85% | |||
| 2024-09-10 | Chief Executive Officer | 33,014 0.1071% | $2.75 | $90,789 | +21.00% | |||
| 2024-09-10 | Chief Financial Officer | 21,118 0.068% | $2.73 | $57,652 | +21.00% | |||
| 2024-09-09 | Chief Executive Officer | 55,579 0.1789% | $2.71 | $150,619 | +21.86% | |||
| 2024-09-09 | director | 25,000 0.0769% | $2.59 | $64,750 | +21.86% | |||
| 2024-09-09 | Chief Financial Officer | 8,194 0.0248% | $2.55 | $20,895 | +21.86% | |||
| 2024-09-09 | director | 13,000 0.0395% | $2.56 | $33,280 | +21.86% | |||
| 2024-01-31 | Chief Executive Officer | 27,460 0.0923% | $4.00 | $109,752 | -10.43% | |||
| 2024-01-31 | CA and CO | 13,670 0.0466% | $4.05 | $55,429 | -10.43% | |||
| 2024-01-31 | Chief Financial Officer | 6,875 0.0235% | $4.06 | $27,943 | -10.43% | |||
| 2024-01-30 | Chief Executive Officer | 40,999 0.1345% | $3.90 | $159,949 | -9.95% | |||
| 2024-01-30 | Chief Financial Officer | 15,000 0.0491% | $3.89 | $58,323 | -9.95% | |||
| 2024-01-30 | CA and CO | 14,500 0.0471% | $3.87 | $56,053 | -9.95% | |||
| 2024-01-29 | Chief Executive Officer | 31,541 0.1037% | $3.71 | $117,036 | -6.12% | |||
| 2024-01-29 | Chief Financial Officer | 10,800 0.035% | $3.65 | $39,450 | -6.12% | |||
| 2024-01-29 | CA and CO | 10,800 0.0349% | $3.65 | $39,438 | -6.12% | |||
| 2023-05-23 | Chief Medical Officer | 10,000 0.0338% | $3.18 | $31,800 | +0.64% | |||
| 2022-12-08 | Chief Executive Officer | 55,250 0.1801% | $2.10 | $115,804 | +37.79% | |||
| 2022-06-30 | Sale | Chief Executive Officer | 4,068 0.0131% | $18.32 | $74,526 | -78.46% |
Insider Historical Profitability
| TRAVERSA SERGIO | Chief Executive Officer | 384024 1.2727% | $3.01 | 9 | 14 | <0.0001% |
| Kelly Paul Edward | director | 212295 0.7036% | $3.01 | 6 | 11 | +87.38% |
| Shenouda Maged | Chief Financial Officer | 88335 0.2928% | $3.01 | 9 | 14 | <0.0001% |
| Ence Chuck | CA and CO | 38970 0.1292% | $3.01 | 3 | 0 | |
| CASAMENTO CHARLES J | director | 13000 0.0431% | $3.01 | 2 | 15 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $5.84M | 4.17 | 1.26M | -4.13% | -$251,564.99 | <0.0001 | |
| Deep Track Capital Lp | $5.77M | 4.11 | 1.24M | -39.35% | -$3.74M | 0.03 | |
| Acadian Asset Management | $5.49M | 3.92 | 1.18M | -0.14% | -$7,617.86 | 0.02 | |
| Parsons Capital Management Inc Ri | $4.53M | 3.23 | 973,520 | +2.49% | +$110,107.35 | 0.3 | |
| Opaleye Management Inc | $3.53M | 2.52 | 759,000 | -13.46% | -$548,700.00 | 0.78 |